坎托·菲茨杰拉德维持Agios Pharmaceuticals(AGIO.US)买入评级
加皇资本市场维持Agios Pharmaceuticals(AGIO.US)买入评级,维持目标价57美元
丰业银行维持Agios Pharmaceuticals(AGIO.US)买入评级,下调目标价至71美元
Agios Pharmaceuticals 分析师评级
H.C. Wainwright维持Agios Pharmaceuticals(AGIO.US)买入评级,上调目标价至61美元
TD Cowen维持Agios Pharmaceuticals(AGIO.US)买入评级
美银证券维持Agios Pharmaceuticals(AGIO.US)买入评级,下调目标价至52美元
摩根大通维持Agios Pharmaceuticals(AGIO.US)持有评级,上调目标价至43美元
加皇资本市场维持Agios Pharmaceuticals(AGIO.US)买入评级,维持目标价57美元
Agios Pharmaceuticals的目标价格由HC Wainwright & Co.维持在每股58.00美元。
Agios Pharmaceuticals 分析师评级
H.C. Wainwright首予Agios Pharmaceuticals(AGIO.US)买入评级,目标价58美元
丰业银行维持Agios Pharmaceuticals(AGIO.US)买入评级,下调目标价至74美元
加皇资本市场维持Agios Pharmaceuticals(AGIO.US)买入评级,维持目标价57美元
美银证券维持Agios Pharmaceuticals(AGIO.US)买入评级,维持目标价54美元
TD Cowen维持Agios Pharmaceuticals(AGIO.US)买入评级
美银证券维持Agios Pharmaceuticals(AGIO.US)买入评级,下调目标价至54美元
美银证券维持Agios Pharmaceuticals(AGIO.US)买入评级,维持目标价55美元
美银证券维持Agios Pharmaceuticals(AGIO.US)买入评级,目标价55美元
TD Cowen维持Agios Pharmaceuticals(AGIO.US)买入评级